An interventional study of Platelet rich plasma (PRP) in Osteochondritis Dissecans, sponsored by University of Colorado, Denver. Completed at 1 site in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-08-05.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
Among 13 studies in Osteochondritis Dissecans with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Osteochondritis Dissecans · United States.
Among the 13 studies in Osteochondritis Dissecans with a site in United States, this one is the only one that started in 2015, is one of 6 with no phase, and was the 6th registered.
30 studies on the registry are indexed under Osteochondritis Dissecans; 7 are open to participants now.
Browse Osteochondritis Dissecans studies →4 of the 13 studies in Osteochondritis Dissecans with a site in United States are open now. Recruiting first, the newest first:
Fin-Ceramica Faenza Spa · Sites in United States, Italy
Ages 18–60
Vericel Corporation · Sites in United States
Ages 10–17
University of Pennsylvania · Sites in United States
Duke University · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Osteochondritis Dissecans studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2015.
This study's enrollment of 15 is below the median of 45 across 17 interventional studies indexed under Osteochondritis Dissecans.
Median enrollment 75 across the 7 interventional studies, 130 across the 6 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 13 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,543 studies on the registry; 317 are open to participants now.
Of its 147 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
University of Colorado, Denver has 1 study filed under Osteochondritis Dissecans — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteochondritis Dissecans with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02664337Duke UniversityConjoint Analysis of Patient Preferences in Joint Interventions | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Osteochondritis Dissecans with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study plans to learn more about ways to treat a joint problem in the knee called Juvenile Osteochondritis Dissecans (OCD). The goal of this study is to see if injecting platelet-rich plasma (PRP) into the knee can help knee cartilage heal faster, and will try to determine whether the injections lead to improvements in pain, performance of activities of daily living, improvements is sports activities and overall function and symptoms reduction. The investigators will compare PRP treatment to conservative therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
Drug: Platelet rich plasma (PRP)
Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
Also known as: autologous PRP
Greater Cartilage Healing Measured by Glycosaminoglycan Content on dGEMRIC MRI
Measured by dGEMRIC MRI
Time frame: 6 months
Improvement in Pain, Performance and Overall Function: IKDC
Measured by the Pediatric IKDC survey results. The International Knee Documentation Committee questionnaire measures knee function, Scores range from 1-100, with higher scores indicating a better outcome.
Time frame: Baseline, 6 months, 12 months
Improvement in Pain, Performance and Overall Function: KOOS, Baseline
Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
Time frame: Baseline
Improvement in Pain, Performance and Overall Function: KOOS, 6 Months
Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
Time frame: 6 Months
Improvement in Pain, Performance and Overall Function: KOOS, 12 Months
Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
Time frame: 12 Months
dGemric MRI Findings Correlate With Measures of Functional Recovery and Symptom Reduction.
Measured by the results of the dGEMRIC MRI and the IKDC and KOOS survey results
Time frame: 6 months
| Milestone | Platelet Rich Plasma (PRP) | Conventional Therapy |
|---|---|---|
| Started | 7 | 8 |
| Completed | 6 | 5 |
| Not completed | 1 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Deemed ineligible following surgery | 1 | 1 |
Measured by dGEMRIC MRI
No measurements were reported for this outcome.
Measured by the Pediatric IKDC survey results. The International Knee Documentation Committee questionnaire measures knee function, Scores range from 1-100, with higher scores indicating a better outcome.
| score on a scale | Platelet Rich Plasma (PRP) | Conventional Therapy |
|---|---|---|
| Baseline | 48 ± 21 | 52 ± 34 |
| Month 6 | 86 ± 21 | 84 ± 20 |
| Month 12 | 84 ± 18 | 90 ± 9 |
Measured by the results of the dGEMRIC MRI and the IKDC and KOOS survey results
Results for this outcome have not been posted.
Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
| score on a scale | Platelet Rich Plasma (PRP) | Conventional Therapy |
|---|---|---|
| Pain Subscale | 56.8 ± 21.6 | 50.0 ± 24.6 |
| Symptoms Subscale | 67.3 ± 24.7 | 65.0 ± 17.0 |
| Activities of Daily Living Subscale | 70.1 ± 24.5 | 60.7 ± 25.2 |
| Sport Subscale | 23.8 ± 21.1 | 30.7 ± 42.2 |
| Quality of Life Subscale | 43.1 ± 19.9 | 28.3 ± 20.3 |
Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
| score on a scale | Platelet Rich Plasma (PRP) | Conventional Therapy |
|---|---|---|
| Pain Subscale | 90.6 ± 15.6 | 91.4 ± 10.6 |
| Symptoms Subscale | 84.6 ± 5.4 | 89.3 ± 12.3 |
| Activities of Daily Living Subscale | 95.8 ± 10.2 | 96.6 ± 3.9 |
| Sport Subscale | 88.1 ± 29.2 | 69.6 ± 40.6 |
| Quality of Life Subscale | 68.1 ± 22.6 | 53.1 ± 32.5 |
Measured by the KOOS survey results. The Knee injury and Osteoarthritis Outcome Score (KOOS) measures patient reported knee function and quality of life. Possible scores range from 0 to 100, with higher scores indicating a better outcome.
| score on a scale | Platelet Rich Plasma (PRP) | Conventional Therapy |
|---|---|---|
| Pain Subscale | 85.9 ± 16.4 | 93.8 ± 8.3 |
| Symptoms Subscale | 92.9 ± 5.0 | 94.0 ± 10.3 |
| Activities of Daily Living Subscale | 90.5 ± 13.1 | 99.2 ± 1.3 |
| Sport Subscale | 75.6 ± 30.8 | 91.7 ± 14.4 |
| Quality of Life Subscale | 56.9 ± 24.2 | 75.0 ± 14.4 |
Collected over 12 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Platelet Rich Plasma (PRP) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Conventional Therapy | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Age, Categorical(Participants) | Platelet Rich Plasma (PRP) | Conventional Therapy | Total |
|---|---|---|---|
| <=18 years | 7 | 8 | 15 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Platelet Rich Plasma (PRP) | Conventional Therapy | Total |
|---|---|---|---|
| Mean | 12 (10 to 13) | 11.335 (10 to 14) | 11.6 (10 to 14) |
| Sex: Female, Male(Participants) | Platelet Rich Plasma (PRP) | Conventional Therapy | Total |
|---|---|---|---|
| Female | 3 | 1 | 4 |
| Male | 4 | 7 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Platelet Rich Plasma (PRP) | Conventional Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 |
| Not Hispanic or Latino | 7 | 6 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Platelet Rich Plasma (PRP) | Conventional Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 8 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Platelet Rich Plasma (PRP) | Conventional Therapy | Total |
|---|---|---|---|
| United States | 7 | 8 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2015 to primary completion in Jan 2020, 58 months.
Results were first posted in Aug 2021, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Platelet rich plasma
University of Colorado, Denver →